Welcome to this UK AstraZeneca produced and funded website
This website is intended for UK Healthcare Professionals only.
The website contains both promotional and non-promotional content.
If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk
For any other UK residents please visit astrazeneca.co.uk
This website is intended for UK Healthcare professionals only. Other UK residents please visit astrazeneca.co.uk
Recommended dosing for the IMFINZI® + LYNPARZA® + CP Regimen in patients with pMMR aEC
Recommended dosing for the IMFINZI® + LYNPARZA® + CP Regimen in patients with pMMR aEC
*For concomitant administration with CY3PA inhibitors, or use in patients with hepatic or renal impairments, please consult the Lynparza 100 mg and 150 mg tablet Summary of Product Characteristics.
Please refer to the Imfinzi SmPC prior to prescribing for safety considerations to minimise the risks associated with its use1
Please refer to the Lynparza SmPC prior to prescribing for safety considerations to minimise the risks associated with its use3
GB-68806 | DOP: September 2025
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling 0800 783 0033.
This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.
